MBRX · Moleculin Biotech, Inc. · Earnings Calls, Transcripts & Webcasts
$7.74
-0.19 (-2.40%)
At close · Nov 20
Return incl. dividend (before tax)
Q1 2025 earnings call transcript
Going-concern doubt
— flagged Nov 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt regarding the Company's ability to continue as a going concern.”View the 10-Q filed Nov 13, 2026
Market Cap
$8.22M
Shares
1.06M
Volume · Nov 20
49.56K
Avg daily vol (24 sessions)
44.57K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Moleculin Biotech, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Moleculin Biotech, Inc. (MBRX), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-09-11
Moleculin Biotech, Inc. (MBRX) September 11, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q1
2025-05-14
Moleculin Biotech, Inc. (MBRX) Q1 2025 Earnings Call Transcript
Confident tone
MIRACLE Phase 3 Trial Progress
Regulatory Approvals and EMA Sign-off
R&D Spend and Manufacturing
Revenue
$0
EPS
$-316.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-24
Moleculin Biotech, Inc. (MBRX) Q4 2024 Earnings Call
Revenue
$0*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Moleculin Biotech, Inc. (MBRX) Q3 2024 Earnings Call Transcript
Confident tone
Annamycin / MIRACLE Phase 3 Trial
Unmet Need in AML
De-risking / Risk Reduction
Revenue
$0
EPS
$-945.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
Moleculin Biotech, Inc. (MBRX) Q2 2024 Earnings Call
Revenue
$0
EPS
$-1185.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
Moleculin Biotech, Inc. (MBRX) Q1 2024 Earnings Call Transcript
Confident tone
First-Line Expansion Opportunity
Regulatory Pathway and End of Phase II Meeting
Combination Therapy Regulatory Risk
Revenue
$0
EPS
$-1305.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-22
Moleculin Biotech, Inc. (MBRX) Q4 2023 Earnings Call Transcript
Confident tone
Annamycin AML second-line efficacy
Regulatory pathway and FDA meeting
Lack of cardiotoxicity
Revenue
$0*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-13
Moleculin Biotech, Inc. (MBRX) Q3 2023 Earnings Call Transcript
Revenue
$0
EPS
$-1410.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-11
Moleculin Biotech, Inc. (MBRX) Q2 2023 Earnings Call Transcript
Revenue
$0
EPS
$-1510.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Moleculin Biotech, Inc. (MBRX) Q1 2023 Earnings Call Transcript
Revenue
$0
EPS
$-2065.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-23
Moleculin Biotech, Inc. (MBRX) Q4 2022 Earnings Call Transcript
Revenue
$0*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Moleculin Biotech, Inc. (MBRX) Q3 2022 Earnings Call Transcript
Revenue
$0
EPS
$-2250.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–12 of 12 webcasts
Key facts
CIK
1659617
CUSIP
60855D507
13F (30d)
32 filings
22 filers
Visit website
Investor relations